NRIX insider buying and SEC filings, explained
Nurix Therapeutics, Inc. · CIK 1549595
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Nov 30
- Former names
- Nurix, Inc.
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$4.0M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 30–Nov 2, 2026 | Planned (10b5-1) | Gwenn Hansen (Chief Scientific Officer) sold 5,409 shares between Oct 30 and Nov 2 at about $26.42 ($143K), marked as a 10b5-1 plan trade. Holdings down 4% to 123,452 shares. | SEC filing Filed Nov 2, 2026, 7:42 PM ET |
| Oct 15, 2026 | Planned (10b5-1) | Gwenn Hansen (Chief Scientific Officer) sold 1,452 shares at $25.00 ($36K), marked as a 10b5-1 plan trade. Holdings down 1% to 117,227 shares. | SEC filing Filed Oct 15, 2026, 5:00 PM ET |
| Oct 2, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 5,786 shares at about $23.19 ($134K), marked as a 10b5-1 plan trade. Holdings down 39% to 9,110 shares. | SEC filing Filed Oct 2, 2026, 5:21 PM ET |
| Sep 2, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 5,787 shares at about $25.76 ($149K), marked as a 10b5-1 plan trade. Holdings down 39% to 9,110 shares. | SEC filing Filed Sep 2, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Gwenn Hansen (Chief Scientific Officer) sold 1,452 shares at $25.47 ($37K), marked as a 10b5-1 plan trade. Holdings down 1% to 117,227 shares. | SEC filing Filed Sep 1, 2026 |
| Aug 5, 2026 | Planned (10b5-1) | Gwenn Hansen (Chief Scientific Officer) sold 4,356 shares at $25.00 ($109K), marked as a 10b5-1 plan trade. Holdings down 4% to 117,227 shares. | SEC filing Filed Aug 5, 2026 |
| Aug 4, 2026 | Planned (10b5-1) | Gwenn Hansen (Chief Scientific Officer) sold 4,111 shares at about $24.36 ($100K), marked as a 10b5-1 plan trade. Holdings down 3% to 117,227 shares. | SEC filing Filed Aug 5, 2026 |
| Aug 4, 2026 | Planned (10b5-1) | Houte Hans van (CFO) sold 4,761 shares at about $24.36 ($116K), marked as a 10b5-1 plan trade. Holdings down 11% to 40,166 shares. | SEC filing Filed Aug 4, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 16,589 shares at about $23.05 ($382K), marked as a 10b5-1 plan trade. Holdings down 65% to 9,110 shares. | SEC filing Filed Aug 3, 2026 |
| Jul 2, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 11,008 shares at about $23.56 ($259K), marked as a 10b5-1 plan trade. Holdings down 45% to 13,579 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 28,935 shares at about $20.06 ($580K), marked as a 10b5-1 plan trade. Holdings down 68% to 13,579 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 25, 2026 | Planned (10b5-1) | Gwenn Hansen (Chief Scientific Officer) sold 5,394 shares at $20.00 ($108K), marked as a 10b5-1 plan trade. Holdings down 4% to 115,005 shares. | SEC filing Filed Jun 25, 2026 |
| Jun 2, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 8,148 shares at about $16.60 ($135K), marked as a 10b5-1 plan trade. Holdings down 38% to 13,579 shares. | SEC filing Filed Jun 2, 2026 |
| May 5, 2026 | Planned (10b5-1) | Houte Hans van (CFO) sold 14,055 shares at about $16.60 ($233K), marked as a 10b5-1 plan trade. Holdings down 27% to 37,592 shares. | SEC filing Filed May 5, 2026 |
| May 4, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 8,148 shares at about $16.96 ($138K), marked as a 10b5-1 plan trade. Holdings down 31% to 18,305 shares. | SEC filing Filed May 4, 2026 |
| May 1, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 5,394 shares at about $16.76 ($90K), marked as a 10b5-1 plan trade. Holdings down 17% to 26,453 shares. | SEC filing Filed May 1, 2026 |
| Apr 2, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 8,148 shares at about $15.24 ($124K), marked as a 10b5-1 plan trade. Holdings down 24% to 26,453 shares. | SEC filing Filed Apr 2, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 8,148 shares at about $15.44 ($126K), marked as a 10b5-1 plan trade. Holdings down 19% to 34,601 shares. | SEC filing Filed Mar 2, 2026 |
| Feb 9, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 14,261 shares at about $16.66 ($238K), marked as a 10b5-1 plan trade. Holdings down 25% to 42,749 shares. | SEC filing Filed Feb 9, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 3,760 shares at about $18.42 ($69K), marked as a 10b5-1 plan trade. Holdings down 7% to 50,897 shares. | SEC filing Filed Jan 20, 2026 |
| Dec 18, 2025 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 3,760 shares at about $17.91 ($67K), marked as a 10b5-1 plan trade. Holdings down 7% to 50,897 shares. | SEC filing Filed Dec 18, 2025 |
| Nov 24, 2025 | Planned (10b5-1) | Christine Ring (Chief Legal Officer) sold 37,600 shares at about $17.07 ($642K), marked as a 10b5-1 plan trade. Holdings down 42% to 50,897 shares. | SEC filing Filed Nov 24, 2025 |
51 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 4:02 PM ET 8-K | Other event (Item 8.01) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow NRIX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.